| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 11, 2026 | Three Swiss biotech companies secure grants |
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, secured a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will suppor... |
| Mar 19, 2026 | Swiss biotechs advance clinical programs across multiple therapeutic areas |
Pilatus Biosciences, a startup based in Vaud, is developing novel immunotherapies for liver and gastrointestinal cancers. Founded in 2022 from the Ludwig Institute for Cancer Research and supported by the Cancer Research Institute, Pilatus... |
| Dec 11, 2025 | Biotechs advance therapies against bacterial infections and peanut allergies |
BioVersys’ novel antibiotic candidate, BV100, an intravenous antibiotic candidate developed to treat severe hospital infections caused by Acinetobacter baumannii, has advanced into a global registration Phase 3 study program in drug-resist... |
| Dec 10, 2024 | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo c... |
| Dec 10, 2024 | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome | AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drug No ... |
| Dec 3, 2024 | Biotech startups celebrate new achievements |
AC Immune, a biopharmaceutical company focused on neurodegenerative diseases, has reported positive interim results from its Phase 2 VacSYn clinical trial evaluating ACI-7104.056, an active immunotherapy targeting alpha-synuclein for early... |
| Nov 14, 2024 | AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease | AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher t... |
| Nov 13, 2024 | AC Immune to Present at the Jefferies 2024 London Healthcare Conference | AC Immune to Present at the Jefferies 2024 London Healthcare Conference
Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative d... |
| Nov 5, 2024 | AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and immunogenicity dataPrescreening rate for Phase 2b Ret... |
| Sep 24, 2024 | Biopharmaceuticals on the Rise: A Surge of Innovation and Investment | The biopharmaceutical sector is buzzing. Recent developments reveal a landscape rich with opportunity and innovation. Companies are securing funding, expanding their reach, and launching groundbreaking therapies. This surge is not just a ri... |
| Sep 24, 2024 | Financial boost for five publicly traded companies |
Altamira Therapeutics, a biopharmaceutical company specializing in RNA-based therapeutics for extrahepatic targets, announced the closing of a public offering raising up to $12.0 million. The offering included Series A-1 and Series A-2 com... |
| Sep 17, 2024 | AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease | AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September... |
| Aug 30, 2024 | US and European approvals open new avenues for Swiss Biotechs |
Life Molecular Imaging (LMI), a partner of AC Immune has received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative c... |
| Aug 6, 2024 | AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update | AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront and total potential milestones of up to a... |
| Jul 31, 2024 | AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 | AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclon... |
| Jul 30, 2024 | AC Immune receives FDA Fast Track Designation for Alzheimer’s Disease |
AC Immune SA is a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The... |
| Jul 25, 2024 | AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease | AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarterPhase 2b ReTain trial is fully funded and conducted by developm... |
| May 28, 2024 | AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 | AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine a... |
| May 13, 2024 | AC Immune inks billion-dollar deal with Takeda |
ACI-24.060 is an immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Amyloid Beta (Abeta) believed to drive plaque formation and Alzheimer’s disease progression. By inducing plaque clearance and... |
| Jan 22, 2024 | Investigators fault Lilly plant for manufacturing issues | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, lots of regulatory content! We talk about march-in rights and chastening TikTok influencers for their prescri... |
| Dec 29, 2023 | AC Immune raises USD50 million | |
| Dec 6, 2023 | Leadership changes with some promotions | |
| Oct 27, 2023 | AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic | PRESS RELEASE
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the first element of a precision medicine approach ... |
| Jul 3, 2023 | AC Immune Showcasing Precision Medicine Programs at AAIC 2023 | /EIN News/ -- AC Immune Showcasing Precision Medicine Programs at AAIC 2023
Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative di... |
| Jun 27, 2023 | AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease | /EIN News/ -- AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA with Investigationa... |
| Jun 23, 2023 | AC Immune Holds Annual General Meeting of Shareholders | /EIN News/ -- AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors
Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmac... |
| Apr 5, 2023 | AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease | /EIN News/ -- AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST
Lausanne, Switzerland, April 5, 2023 – AC I... |
| Feb 2, 2023 | AC Immune to Present at the SVB Securities Global Biopharma Conference | /EIN News/ -- AC Immune to Present at the SVB Securities Global Biopharma Conference
Lausanne, Switzerland, February 2, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurode... |
| Nov 23, 2022 | AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference | Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s disease New data on anti-phospho-Tau vaccines confirm safety, tolerability and immunogenicity of ACI-35 and JACI-35, ... |
| Oct 28, 2022 | AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update | Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome
Received regulatory clearance to initiate an ada... |
| Oct 28, 2022 | AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update | Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome
Received regulatory clearance to initiate an ada... |
| Oct 4, 2022 | AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome | Interim analysis expected around year-end 2022, informing Phase 2 start
Trial progressing with regulatory clearances in the UK and also now in Spain
Planned submission of U.S. Investigational New Drug application in Q1 2023
Continues progre... |
| Oct 4, 2022 | AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome | Interim analysis expected around year-end 2022, informing Phase 2 start
Trial progressing with regulatory clearances in the UK and also now in Spain
Planned submission of U.S. Investigational New Drug application in Q1 2023
Continues progre... |
| Sep 26, 2022 | AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease | AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product development
LAUSANNE, Switzerland, Sept. 26,... |
| Sep 1, 2022 | AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent | Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from ... |
| Aug 24, 2022 | AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases | Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalities
Integrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-... |
| Aug 11, 2022 | AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases | Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CETDiscussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches
LAUSANNE, Switzerland, Aug... |
| Aug 2, 2022 | Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC | Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences favoring crenezumab over placebo were confirmed across the co-primary, multiple secondary... |
| Jul 28, 2022 | AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update | Three clinical readouts delivered year to date; four more expected by year-end
First patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrom... |
| Jul 22, 2022 | AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference | New data from the API ADAD Study to be presented in AAIC Focused Topic Session
New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease
First-time presentation of innovative biomarker-based ... |
| Jun 24, 2022 | AC Immune Holds Annual General Meeting of Shareholders | LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual ... |
| Jun 16, 2022 | AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease | Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease
Numerical differences favouring crenezumab over placebo were observed a... |
| May 31, 2022 | AC Immune to Present at the 2022 Jefferies Healthcare Conference | LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will parti... |
| May 17, 2022 | AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award | LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Dr. Andrea Pfeifer, CEO and a... |
| May 9, 2022 | AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology | First study of an anti-Abeta vaccine in people living with Down syndrome (DS)
Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine
Optimized formulation of the ACI-24 vaccine to e... |
| Apr 28, 2022 | AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update | Two clinical readouts delivered in Q1; five more expected by year-end
Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine
First images of alph... |
| Apr 27, 2022 | AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference | LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will par... |
| Apr 8, 2022 | AC Immune Reports Changes to Senior Management | Howard Donovan appointed Chief HR Officer, joins executive committee
Joerg Hornstein, CFO, will leave to pursue new role
Chris Roberts promoted to Vice President, Finance and appointed Interim CFO
Julian Snow promoted to Vice President, U.S... |
| Mar 30, 2022 | AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases | a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics
Another first for validated Morphomer® discovery technology platform in developi... |
| Mar 22, 2022 | AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update | Seven clinical data readouts expected in 2022
Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022
Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022
Initiation of ACI-24 anti-Abeta... |
| Mar 21, 2022 | AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases | LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, will host a key opinion leader (KOL)... |
| Mar 16, 2022 | AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference | ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers
A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson’s disease, Lewy Body Dementia, MSA and o... |
| Feb 28, 2022 | AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs | Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)
AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery for a-synucleinopathies
LAUSANNE, Switze... |
| Feb 15, 2022 | AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort | Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment
ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or high-dose cohorts to da... |
| Feb 4, 2022 | AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease | Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development
Strong response against neurotoxic pyroGlu-Abeta variants observed in non-human primates
Data further support advancing optimized ACI-24 into the next stag... |
| Feb 2, 2022 | AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference | LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will part... |
| Dec 15, 2021 | AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs | Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD)
Programs targeting intracellular disease mechanisms complemen... |
| Nov 12, 2021 | AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response | Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment
New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development
LAUSANNE, Switzerland, Nov. 12,... |
| Nov 12, 2021 | AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Potent Immune Response | Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment
New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development
LAUSANNE, Switzerland, Nov. 12,... |
| Nov 10, 2021 | AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease | Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo
Ben... |
| Nov 8, 2021 | AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update | Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease
Closed its strategic acquisition of an industry-leading Parkinson’s disease vaccine and an equity financing led b... |
| Nov 8, 2021 | AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update | Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease
Closed its strategic acquisition of an industry-leading Parkinson’s disease vaccine and an equity financing led b... |
| Nov 4, 2021 | AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases | LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is extending its r... |
| Nov 2, 2021 | New Data on AC Immune’s Abeta and pTau Clinical Programs in Alzheimer’s Disease To Be Presented at CTAD 2021 | LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigatio... |
| Nov 2, 2021 | New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021 | LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigatio... |
| Oct 29, 2021 | AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors | Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization
Prof. Bütler is a leading Swiss economist and former Vice President of t... |
| Oct 25, 2021 | AC Immune to Present at the Jefferies London Healthcare Conference | LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will part... |
| Sep 3, 2021 | AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year | LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and C... |
| Sep 2, 2021 | Fünf Unternehmerinnen und Unternehmer am SEF 2021 ausgezeichnet | |
| Aug 31, 2021 | AC Immune’s antibody shows therapeutic effect in Alzheimer’s patients | |
| Jul 28, 2021 | AC Immune acquires Parkinson’s disease vaccine candidate and equity investment | Parkinson's disease is causally linked to pathological aggregation and deposition of a-syn, a drug target that has been validated in clinical studies using monoclonal antibodies. Austrian clinical-stage biopharmaceutical company Affiris dev... |
| Jul 28, 2021 | AC Immune : ACIU Conference Call Presentation | Strategic Acquisition of Industry-leading
Parkinson's Disease Vaccine
NASDAQ: ACIU | July 2021
www.acimmune.com
Disclaimer
This presentation contains statements that constitute "forward-looking statements" within the meaning of Se... |
| Jul 27, 2021 | AC Immune picks up Phase 2-ready drug for Parkinson’s in $58M deal with Affiris | AC Immune is expanding its prospects in Parkinson’s disease with a deal to acquire drug programs from Affiris that address a promising target in the neurodegenerative disorder. The assets include one drug candidate that’s ready to advance t... |
| Jul 27, 2021 | AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH | All-stock transaction maintains AC Immune’s strong cash position
USD 25 million private placement led by premier investor Athos Service GmbH
Transactions expand and accelerate AC Immune’s therapeutic development in Parkinson’s disease
AC Im... |
| Jul 27, 2021 | Looking to replicate Covid-19 success in neuro, BioNTech backers bet on AC Immune and its newly-acquired Parkinson's vaccine | The German billionaires behind BioNTech have found a new vaccine project to back.
Through their family office Athos Service, twin brothers Thomas and Andreas Strüngmann are leading a $25 million private placement into Swit... |
| Jun 1, 2021 | AC Immune : Publication of official invitation in the Swiss Official Gazette of Commerce | Category: Notifications issued to company members
Sub-category: Invitation to the General Meeting
Publication date: SHAB 01.06.2021
Expected expiry date: 01.06.2022
Publication number: UP04-0000003429
Publishing entity
Bär & Karrer AG, ... |
| Apr 4, 2021 | Here are the 100 best early-stage investors, according to data analysis from Tribe Capital | Hello everyone!
Advertisement
Welcome to this weekly roundup of stories from Insider's Business co-Editor in Chief Matt Turner. Subscribe here to get this newsletter in your inbox every Sunday.
What we're going over today:
Complimentary Tec... |
| Apr 4, 2021 | Here are the 100 best early-stage investors, according to data analysis from Tribe Capital | Hello everyone!
The best early-stage investors
From Margaux MacColl, Melia Russell, Candy Cheng, and Michael Haley:
The venture capitalists who write the earliest checks – known as seed investors – take the biggest risks. But when they choo... |
| Mar 31, 2021 | AC IMMUNE SA
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease | LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss t... |
| Mar 16, 2021 | AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine | Topline ACI-24 Phase 1b immunogenicity and safety results reported today at a global Down syndrome symposium
Reported new data in non-human primates for optimized vaccine formulation which shows strong response against key pathological Abet... |
| Mar 9, 2021 | AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases | Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43
First biologically active small molecule inhibitors of intracellular ... |
| Feb 24, 2021 | AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference | LAUSANNE, Switzerland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that four new data pr... |
| Feb 11, 2021 | AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study | Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease
ACI-35.030 was safe and well tolerated with no safety conce... |
| Dec 29, 2020 | Grants for companies fighting HIV, neurodegenerative diseases and drug resistance | |
| Dec 29, 2020 | Grants for companies fighting HIV, neurodegenerative diseases and drug resistance | CRISPR Therapeutics received a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV. The grant builds upon CRISPR Therapeutics’ proprietary CRISPR/Cas9 gene editing technolog... |
| Dec 11, 2020 | Finalistinnen des ersten SEF.WomenAwards stehen fest | Das Swiss Economic Forum (SEF) verleiht Frauen mit einem herausragenden unternehmerischen Leistungsausweis den SEF.WomenAward und schafft damit gleichzeitig eine Plattform für Unternehmerinnen. Dabei werden Unternehmerinnen in den Kategorie... |
| Dec 11, 2020 | Finalistinnen des ersten SEF.WomenAwards stehen fest | |
| Aug 3, 2020 | AC Immune’s therapeutic and diagnostic programs for Parkinson’s achieve milestones | AC Immune, a clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced it is one of the winners of the Ken Griffin Alpha-synuclein Imaging Competition from The Michael J. Fox Foundation ... |
| Aug 3, 2020 | AC Immune’s therapeutic and diagnostic programs for Parkinson’s achieve milestones | |
| Sep 24, 2019 | Eli Lilly dishes out first milestone payment for Alzheimer's deal; ADC Therapeutics, Viela Bio set terms for IPO | → With others shying away from the Alzheimer’s field after the many clinical implosions and disasters, Eli Lilly is still chugging along with its $2 billion deal with AC Immune — despite its share of BACE woes. AC Immune is s... |
| Jun 19, 2019 | “With setbacks, the most important thing is to show strength” | |
| Dec 14, 2018 | AC Immune and Eli Lilly sign billion-dollar agreement | |
| Nov 2, 2017 | AC Immune to receive milestone payment from Genentech | |
| Sep 23, 2016 | AC Immune raises more than CHF 50 million in its IPO | |
| Sep 23, 2016 | AC Immune upsizes IPO, hits bottom of range, netting $58M for neurodegeneration R&D | AC Immune ($ACIU) has pulled off the potentially tricky task of persuading investors to back its IPO. The Genentech-partnered neurodegeneration specialist is offloading 6 million shares, 32% more than originally planned, at the bottom end o... |
| Sep 22, 2016 | Alzheimer’s player AC Immune taps IPO for $58M raise, sees shares soar | AC Immune CEO Andrea Pfeifer
Swiss biotech AC Immune followed through on its IPO $ACIU today, pricing at $11 a share . That’s the low end of the range, but the company bumped the net to $58 million by adding 1.5 million shares, in... |
| Sep 14, 2016 | Genentech-partnered AC Immune tees up $68M IPO to bankroll Alzheimer's R&D | AC Immune has set the terms for its long-mooted Nasdaq IPO. The Alzheimer’s specialist, which lists Biogen ($BIIB), Genentech and Johnson & Johnson ($JNJ) among its partners, is looking to raise as much as $68 million (€61 million), the... |
| Jul 7, 2016 | AC Immune to receive CHF14 million under collaboration agreement with Genentech | |
| Jun 1, 2016 | AC Immune files for IPO | |
